Nkarta, Inc. (NKTX) SEC Filings & Earnings Calls

No approved products and history of losses

“We have incurred significant losses since our inception and we expect to continue to incur significant losses for the foreseeable future. We have never generated revenue from product sales and may never achieve or maintain profitability.” · word for word

Need for additional capital

“We will require additional capital, which, if available, may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.” · word for word

Dependence on NKX019 clinical success

“Our business is highly dependent on the clinical success of our product candidates, and on the clinical success of NKX019, in particular.” · word for word

Clinical-stage company with no approved products or revenue; net loss and cash burn continue

“Net loss of $40.4M; no revenue reported; cash burn expected to continue”

No revenue; pre-commercial stage with significant R&D spending and net losses.

“Net loss of $27.8M; no product revenue.”

Clinical trial execution risk; data readout expected in 2026 but no guarantee of success.

“Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026.” · word for word

Cash burn risk

“As of March 31, 2026, the Company had an accumulated deficit of $676.1 million and cash, cash equivalents, restricted cash and investments of $266.7 million.” · word for word

Clinical trial risk

“Clinical development involves a lengthy and expensive process with an uncertain outcome, and we may encounter substantial delays due to a variety of reasons outside our control.” · word for word

Dependence on NKX019

“Our business is highly dependent on the clinical success of our product candidates, and on the clinical success of NKX019, in particular.” · word for word

Dilution risk from potential issuance of up to $100M in common stock

“ATM program for up to $100M; no revenue; pre-commercial stage”

NOL limitation risk

“if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, Sections 382 and 383 of the Code limit the corporation’s ability to use carryovers of its pre-change NOLs.” · word for word

Stock price volatility

“The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors.” · word for word

Clinical-stage company with no approved products or revenue; net loss and cash burn continue

“Net loss of $104.1M; no revenue reported; cash burn expected to continue”

Clinical-stage company with no approved products or revenue; net loss and cash burn continue

“Net loss of $21.7M; no revenue reported; cash burn expected to continue”

Clinical development risk

“We have incurred significant losses since our inception and we expect to continue to incur significant losses for the foreseeable future.” · word for word

Capital requirement risk

“We will require additional capital, which, if available, may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.” · word for word

Competitive risk

“If we fail to compete effectively with academic institutions and other biopharmaceutical companies that develop similar or alternatives to cellular immunotherapy product candidates, our business will be materially adversely affected.” · word for word